|Bid||77.98 x N/A|
|Ask||81.52 x N/A|
|Day's range||78.56 - 80.06|
|52-week range||72.84 - 89.28|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||8.96|
|Forward dividend & yield||3.10 (3.75%)|
|Ex-dividend date||08 Mar 2022|
|1y target est||N/A|
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like a
Novartis ( VTX:NOVN ) Full Year 2022 Results Key Financial Results Revenue: US$51.8b (down 2.0% from FY 2021). Net...
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.